AU2003287945A1 - Mutant protein and refolding method - Google Patents

Mutant protein and refolding method

Info

Publication number
AU2003287945A1
AU2003287945A1 AU2003287945A AU2003287945A AU2003287945A1 AU 2003287945 A1 AU2003287945 A1 AU 2003287945A1 AU 2003287945 A AU2003287945 A AU 2003287945A AU 2003287945 A AU2003287945 A AU 2003287945A AU 2003287945 A1 AU2003287945 A1 AU 2003287945A1
Authority
AU
Australia
Prior art keywords
mutant protein
refolding method
refolding
frpb protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287945A
Other languages
English (en)
Other versions
AU2003287945A8 (en
Inventor
Ralph Biemans
Philippe Denoel
Christiane Feron
Carine Goraj
Jeroen Kortekaas
Jan Poolman
Jan Tommassen
Vincent Weynants
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
TECHNOLOGY FOUNDATION (STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN)
Universiteit Utrecht
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2003287945A8 publication Critical patent/AU2003287945A8/xx
Publication of AU2003287945A1 publication Critical patent/AU2003287945A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003287945A 2002-08-30 2003-08-28 Mutant protein and refolding method Abandoned AU2003287945A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220199.4 2002-08-30
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
PCT/EP2003/009634 WO2004020463A2 (en) 2002-08-30 2003-08-28 Mutant protein and refolding method

Publications (2)

Publication Number Publication Date
AU2003287945A8 AU2003287945A8 (en) 2004-03-19
AU2003287945A1 true AU2003287945A1 (en) 2004-03-19

Family

ID=9943242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287945A Abandoned AU2003287945A1 (en) 2002-08-30 2003-08-28 Mutant protein and refolding method

Country Status (10)

Country Link
US (1) US20060141563A1 (cg-RX-API-DMAC7.html)
EP (1) EP1572729B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006516183A (cg-RX-API-DMAC7.html)
AT (1) ATE481983T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003287945A1 (cg-RX-API-DMAC7.html)
CA (1) CA2495086A1 (cg-RX-API-DMAC7.html)
DE (1) DE60334316D1 (cg-RX-API-DMAC7.html)
ES (1) ES2351598T3 (cg-RX-API-DMAC7.html)
GB (1) GB0220199D0 (cg-RX-API-DMAC7.html)
WO (1) WO2004020463A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
CA2654706A1 (en) * 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine
JP5568017B2 (ja) * 2008-12-25 2014-08-06 一般財団法人化学及血清療法研究所 組換え鶏伝染性コリーザワクチン及びその製造方法
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
CA2811699C (en) * 2010-09-28 2019-07-02 Abera Bioscience Ab Fusion protein for secretory protein expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
DE69636739T2 (de) * 1995-12-21 2007-10-18 Ajinomoto Co., Inc. Verfahren zur rückfaltung von menschlichem activin a
NZ520445A (en) * 2000-01-25 2004-02-27 Univ Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA

Also Published As

Publication number Publication date
AU2003287945A8 (en) 2004-03-19
JP2006516183A (ja) 2006-06-29
US20060141563A1 (en) 2006-06-29
EP1572729A2 (en) 2005-09-14
WO2004020463A3 (en) 2005-08-18
WO2004020463A2 (en) 2004-03-11
GB0220199D0 (en) 2002-10-09
ES2351598T3 (es) 2011-02-08
DE60334316D1 (de) 2010-11-04
ATE481983T1 (de) 2010-10-15
EP1572729B1 (en) 2010-09-22
CA2495086A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
DE60036641D1 (de) Mutanter apre promoter
AU2003275612A1 (en) Defructosylation method
AU2003299585A1 (en) Water-soluble products and methods of making and using the same
AU2003212729A1 (en) Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
EP2455457A3 (en) Covalent tethering of functional groups to proteins
AU2003203089A1 (en) Segmented side-to-side faims
AU2003270626A1 (en) Magnetically modified electrodes as well as methods of making and using the same
EP1283235A3 (en) Composition, method of making, and method of using adhesive composition
AU2003213580A1 (en) Subtilisin carlsberg proteins with reduced immunogenicity
AU2002354696A1 (en) Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme
AU2003217325A1 (en) Complex technologies using enzymatic protein hydrolysate
AU2003287945A1 (en) Mutant protein and refolding method
AU2003248117A1 (en) Novel enzyme forming peptide, microorganism producing the same and process for producing dipeptide using them
AU2003212526A1 (en) Arrays of cytosolic accessory proteins immobilized on a surface and pertinent methods
AU2003210226A1 (en) Method for predicting the expression efficiency in cell-free expression systems
AU2002365903A1 (en) Method for the generation of proteins with new enzymatic function
WO2003035683A8 (en) Surfactant protein-d and atherosclerosis
WO2005057486A3 (en) Protein engineering with analogous contact environments
AU2003228597A1 (en) ANTIBODIES FOR ENZYMES OF THE Omega-OXIDATION PATHWAY AND METHODS RELATING THERETO
AU2001234916A1 (en) Eto1 and related proteins, and methods of regulating ethylene biosynthesis
WO2004078936A3 (en) Methods for preventing gluconoylation of proteins
WO2003040393A3 (en) Nucleic acids encoding proteases
AU2003276423A1 (en) Digoxin labelled proteins and production and uses thereof
AU2003254630A1 (en) Method for the production of an artificial polypeptide and artificial proteins produced by said method
AU2003263751A1 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 17, PAGE(S) 4901 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME GLAXOSMITHKLINE BIOLOGICALS SA, APPLICATION NO. 2003287945, UNDER INID (71) CORRECT THE NAME TO READ GLAXOSMITHKLINE BIOLOGICALS SA; UTRECHT UNIVERSITY; TECHNOLOGY FOUNDATION (STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN); GORAJ, CARINE